An observational study in Aging and Obesity & Overweight, sponsored by National University of Singapore. Not yet recruiting at 2 sites in Singapore. Open to participants aged 40 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by National University of Singapore · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.
Among the 83 studies in Obesity with a site in Singapore, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 9 that started in 2026, is one of 15 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 75th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 21–70 · Healthy volunteers
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 40 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 440 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 70 across the 68 interventional studies, 200 across the 15 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.
National University of Singapore has 7 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07225556Eli Lilly and CompanyA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy | 2026-12 |
| NCT07444073National University of SingaporeAssessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | 2026-12-31 |
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Obesity with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
This study will evaluate whether routine treatment with semaglutide or tirzepatide, prescribed in conjunction with lifestyle coaching support as part of standard-of-care in a real-world clinical weight-loss program, is associated with changes in biological age as measured by the LinAge2 clock. Aging is a primary driver of chronic disease, functional decline, and mortality. Obesity, through mechanisms such as mitochondrial dysfunction, oxidative stress, and chronic inflammation, may accelerate biological aging. Given that GLP-1 receptor agonists such as semaglutide and tirzepatide improve metabolic and cardiovascular health, this study will examine whether these benefits extend to biological aging as quantified by LinAge2, a clinical aging clock derived from standard clinical biomarkers.
This is a six-month prospective observational cohort study involving approximately 440 adults aged 40-89 years who are overweight or obese and newly enrolled in the weight management program at NOVI Health (T3 Health PTE LTD), a private healthcare provider in Singapore. Clinical care and program delivery are provided by NOVI Health as part of routine practice. Participants will receive standard-of-care GLP-1 RA therapy (semaglutide or tirzepatide) together with personalized diet and physical activity interventions. Study procedures include baseline and six-month visits at the NOVI Health clinic, where anthropometry, body composition, blood and urine samples, questionnaires, and functional performance assessments will be conducted. Blood and urine samples will be collected by trained and certified nurses or phlebotomists, analyzed by an accredited external laboratory, and discarded thereafter; no biological materials will be stored.
The National University of Singapore (NUS) research team provides scientific leadership in study design and conducts the development and application of the LinAge2 biological aging clock and analyses of de-identified data generated during routine clinical care at NOVI Health. NUS is not involved in participant recruitment, informed consent, clinical procedures, drug prescription, or biospecimen handling. The primary outcome is change in LinAge2 biological age from baseline to six months. Secondary outcomes include changes in body composition, cardiometabolic biomarkers, and functional clinical measures.
Adults aged 40-89 years who are overweight or obese and newly enrolled in the NOVI Health weight management program in Singapore. Participants are selected from routine clinical practice at the NOVI Health clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults newly enrolled in the NOVI Health weight management program receiving standard-of-care GLP-1 receptor agonist therapy (semaglutide or tirzepatide) and lifestyle coaching (diet and physical activity) as part of routine clinical care. Medication type is determined by routine clinical care and patient-clinician decision-making, not by the research study.
Other: Not applicable. This is an observational study.
Not applicable. This is an observational study.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
LinAge2 Biological Age
The primary outcome of this study is to determine the change in LinAge2 biological age estimates in response to the NOVI Health weight management program, which comprises GLP-1 RA therapy alongside personalized diet and physical activity interventions.
Time frame: Baseline and 6 months
Change in Body Composition: Body Weight
Body weight measured in kilograms (kg); outcome is change from baseline to 6 months.
Time frame: Baseline and 6 months
Change in Body Composition: Body Mass Index (BMI)
BMI calculated as weight (kg) divided by height (m²), reported in kg/m².
Time frame: Baseline and 6 months
Change in Body Composition: Waist Circumference
Waist circumference measured in centimeters (cm) using a measuring tape
Time frame: Baseline and 6 months
Change in Body Composition: Hip Circumference
Waist circumference measured in centimeters (cm) using a measuring tape
Time frame: Baseline and 6 months
Change in Body Composition: Waist-to-Hip Ratio
Waist-to-hip ratio calculated as waist circumference / hip circumference
Time frame: Baseline and 6 months
Change in Pulse Rate
Pulse rate measured in beats per minute (bpm)
Time frame: Baseline and 6 months
Change in Blood Pressure
Systolic and Diastolic blood pressure measured in mmHg
Time frame: Baseline and 6 months
Change in Body Composition: Body Fat Percentage
Body fat percentage (%) measured using a Tanita body composition analyzer (bioimpedance)
Time frame: Baseline and 6 months
Change in Body Composition: Muscle Mass
Muscle mass measured in kilograms (kg) using a Tanita body composition analyzer (bioimpedance)
Time frame: Baseline and 6 months
Change in Body Composition: Basal Metabolic Rate
Basal metabolic rate measured in kilocalories per day (kcal/day) as estimated by a Tanita body composition analyzer (bioimpedance)
Time frame: Baseline and 6 months
Change in Body Composition: Metabolic Age
Metabolic age (years) estimated by a Tanita body composition analyzer (bioimpedance)
Time frame: Baseline and 6 months
Change in Functional Clinical Measures: Handgrip Strength (Southampton protocol)
Handgrip strength measured using a handheld dynamometer following the Southampton protocol; reported in kilograms (kg)
Time frame: Baseline and 6 months
Change in Functional Clinical Measures: Change in Chester Step Test Estimated VO₂max
Chester Step Test performed to estimate VO₂max, reported in mL/kg/min
Time frame: Baseline and 6 months
Change in Functional Clinical Measures: Change in Five-Times Sit-to-Stand Test Time
Time to complete five sit-to-stand repetitions, reported in seconds
Time frame: Baseline and 6 months
Change in Cardiometabolic: Glycohemoglobin (HbA1c)
Glycohemoglobin measured as percent (%)
Time frame: Baseline and 6 months
Change in Cardiometabolic: Glucose
Glucose measured in mmol/L
Time frame: Baseline and 6 months
Change in Cardiometabolic: Total Cholesterol
Total cholesterol measured in mmol/L
Time frame: Baseline and 6 months
Change in Cardiometabolic: High-Density Lipoprotein (HDL) Cholesterol
HDL cholesterol measured in mmol/L
Time frame: Baseline and 6 months
Change in Cardiometabolic: Triglycerides
Triglycerides measured in mmol/L
Time frame: Baseline and 6 months
Change in Cardiometabolic: C-Reactive Protein (CRP)
C-reactive protein measured in mg/dL
Time frame: Baseline and 6 months
Change in Hepatic: Alanine Aminotransferase (ALT)
ALT measured in U/L
Time frame: Baseline and 6 months
Change in Hepatic: Aspartate Aminotransferase (AST)
AST measured in U/L
Time frame: Baseline and 6 months
Change in Renal: Serum Creatinine
Creatinine measured in µmol/L
Time frame: Baseline and 6 months
Change in Renal: Blood Urea Nitrogen
Blood urea nitrogen measured in mmol/L
Time frame: Baseline and 6 months
Change in Renal: Urine Albumin
Urine albumin measured in mg/L
Time frame: Baseline and 6 months
Questionnaire: PAR-Q Physical Activity Readiness Questionnaire
PAR-Q questionnaire (7 items). Reported as number of "Yes" responses (0-7)
Time frame: Baseline and 6 months
Questionnaire: Smoking status
Self-reported smoking status assessed by questionnaire and categorized as current smoker, former smoker, or never smoker.
Time frame: Baseline and 6 months
Questionnaire: Self-reported health
Question 1: General health condition. Self-rated general health assessed by a single questionnaire item with 5 response options (Excellent, Very good, Good, Fair, Poor). Question 2: Health compared with 1 year ago. Self-rated health compared with 1 year ago assessed by a single questionnaire item with response options (Better, About the same, Worse).
Time frame: Baseline and 6 months
Questionnaire: Co-morbidity index (22 conditions)
Number of self-reported comorbidities from a prespecified 22-condition (hypertension, diabetes mellitus, renal impairment, asthma, anemia, arthritis, coronary heart disease, angina, previous myocardial infarction, previous stroke, emphysema, thyroid disease, obesity, chronic bronchitis, liver disease, malignancy, osteoporosis, previous hip fracture, previous wrist fracture, previous spine fracture, cognitive impairment, and overnight hospitalization)
Time frame: Baseline
Questionnaire: Healthcare use index
Self-reported number of healthcare visits in the past 12 months (count). From None to 13 times or more.
Time frame: Baseline
Plan to share: Undecided — De-identified individual participant data (IPD) underlying the results reported in publications will be shared upon reasonable request after primary publication. Requests will be reviewed by the study team and require a data use agreement. Data will be provided in de-identified form and will not include direct identifiers.
Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 6 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University of Singapore →